<![CDATA[FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.]]>

Oxytocin in the amygdala links social and reward signals to cataplexy in mice

Nature Neuroscience, Published online: 14 July 2026; doi:10.1038/s41593-026-02349-2

Loss of orexin neurons in narcolepsy leads to sleepiness and cataplexy episodes, which are most common in social contexts. In a mouse model, an oxytocin-sensitive circuit in the central amygdala is both necessary and sufficient for cataplexy induced by socialization and reward, which links positive emotional signals to motor suppression and highlights a potential therapeutic target.

<![CDATA[Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.]]>
<![CDATA[Experts explain why most narcolepsy patients need combination therapy, not one pill, and how new agents cut daytime sleepiness toward normal.]]>
<![CDATA[Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.]]>
<![CDATA[Learn how DEA scheduling shapes narcolepsy treatment choices, and why emerging orexin agonists may transform daytime sleepiness and cataplexy care.]]>
<![CDATA[Experts explain which narcolepsy meds suit kids—oxybates and pitolisant approvals, stimulant side effects, and key heart-safety checks.]]>
<![CDATA[Explore today’s narcolepsy care: wake-promoting meds, oxybates for cataplexy, and pitolisant’s histamine boost—plus sleep habits that matter.]]>
<![CDATA[Explore today’s narcolepsy care: from sleep hygiene to stimulants, oxybates, and pitolisant—targeting sleepiness and cataplexy.]]>